Using an evolutionary epidemiological model of pandemics to estimate the infection fatality ratio for humans infected with avian influenza viruses

Joshua Mack[1*], Michael Li[2,3], Amy Hurford[1,4],

[1]Department of Biology, Memorial University, St. John's, Newfoundland and Labrador, Canada

[2]Modelling Hub, Science and Policy Integration Branch, Public Health Agency of Canada, Guelph, Ontario, Canada

[3]Department of Mathematics and Statistics, McMaster University, Hamilton, Ontario, Canada

[4]Department of Mathematics and Statistics, Memorial University, St. John's, Newfoundland and Labrador, Canada

Keywords: Avian Influenza, Pandemic, Zoonotic Spillover, Human Infection, Mathematical Model, Infection Fatality Ratio, Evolutionary Epidemiology

E-mail: jmmack@mun.ca (JM)

Abstract

The risk of highly pathogenic avian influenza virus infection to humans is challenging to estimate as many human avian influenza virus (AIV) infections are undetected because infections may be asymptomatic, symptomatic but not tested, and difficult to identify through contact tracing, as human-to-human transmission is rare. We derive equations that consider the evolutionary mechanisms that give rise to pandemics and are parameterized to be consistent with records of past pandemics. We estimate that thousands of human AIV infections occur worldwide in an average year and estimate the infection fatality ratio as 32 deaths per 10,000 infections (95% confidence interval: [9.6, 75]). This estimate is comparable to SARS-CoV-2 during the recent pandemic and higher than seasonal human influenza. We estimate that preventing animal-to-human influenza spillovers would delay pandemic emergence by several years. Preventing human infections with AIV is necessary given the high risk of severe outcomes to individuals and to reduce the risk of pandemics occurring in the future.

1. Introduction

The spread of highly pathogenic avian influenza (HPAI) virus in animals poses a risk to humans both individually, due to the risk of avian influenza virus (AIV) infections that result in severe outcomes, and collectively, due to the risk that AIV adapts to transmit effectively in humans and causes a pandemic. Past influenza pandemics have occurred due to reassortment between human influenza virus and AIV resulting in strains that spread between humans [1]. Reassortment is the swapping of gene segments between viruses [2] and is a mechanism for the evolution of mammalian-adapted strains of HPAI virus [3]. Recent AIV outbreaks have occurred in wild birds, poultry, and mammals, with some human infections reported. In 2022, HPAI virus spread across North America and caused mass mortality among wild birds in Canada with tens of thousands of birds reported sick or dead [4;5]. An HPAI virus outbreak in U.S. poultry and cattle has infected 71 people since March 2024 [6]. The currently circulating H5 HPAI virus strains have not yet adapted to spread well in humans, and of these recent infections there is no evidence of ongoing human-to-human spread [7]. Recent HPAI H5N1 virus transmission events among mammals include farmed mink in Europe and marine mammals in South America [8], and mammalian-adapted substitutions have been found in recovered viruses from infected mammals in Canada [3].

The transmissibility of AIV from animals-to-humans, human-to-human, and the pathogenicity of AIV infections in humans depends on characteristics of the influenza virus and host factors. Influenza virus virions have two surface envelope proteins: hemagglutinin (HA) and neuraminidase (NA). HA binds to sialic acid whose presence, location and structure vary between species which is a major reason for host specificity. There are 18 HA subtypes and 9 NA subtypes with H5 and H7 being able to mutate from low pathogenic to highly pathogenic [9,10]. Zoonotic spillover refers to the spread of a pathogen from animals to humans [11]. For zoonotic

spillover events, the introduced strain typically cannot yet spread between humans but may
evolve into an adapted strain through reassortment and/or mutation that enables human-to-human
transmission and could ultimately lead to a pandemic [12,13].

HPAI H5N1 virus of the A/goose/Guangdong/1/1996 lineage emerged in Asia in 1996 and
since 2003, 986 human cases have been reported around the world with 473 deaths,
corresponding to a case fatality ratio of 48% [14,15]. Yet the case fatality ratio (the number of
deaths per case) likely does not describe the risk that HPAI virus poses to humans, as only some
infections are reported as cases, and many human infections are undetected as they may be
asymptomatic or symptomatic but not tested. In addition, as there are few secondary infections in
humans [16], contact tracing to detect infections is usually not possible. By combining
observations describing the occurrence of pandemics in the past with a model that describes the
epidemiological and evolutionary processes that occur when an animal strain of influenza adapts
to cause a pandemic, we can estimate how many human influenza infections of zoonotic origin
are occurring annually. The infection fatality ratio (IFR) is the number of mortalities per
infection [17] and more accurately quantifies the risk of a severe outcome occurring in a person
that is infected with HPAI virus. We will use our approach to estimate the IFR of AIV in humans,
which can be understood as a historical average that is also an average across the different AIV
subtypes.

The benefit of preventing human infections with AIV is not only to the individual, as can be
quantified by the IFR, but also to reduce the chance that evolutionary change occurs resulting in
a pandemic. We use our modelling approach to estimate the effect of preventing human
infections with AIV on delaying the time until the next pandemic. Previous studies have
modelled the transmission of HPAI virus between birds and mammals [18;19], HPAI virus
spillover to humans [20], and the human-human transmissibility of HPAI virus using outbreak
data [21]. Our approach overcomes the challenge of limited surveillance to detect asymptomatic
human AIV infections. The objectives of this study are to estimate the number of human
infections with AIV that occur annually, estimate the IFR of human AIV infections, and
determine how preventing zoonotic spillovers of AIV to humans would delay a future pandemic.

2. Methods

(a)   Model formulation

To develop the model to estimate the annual number of human AIV infections from the historical
rate of pandemics, we adapt the approach of Day et al., 2006 [13] who estimated the minimum
annual number of human AIV infections. Instead of using analytical approximations to calculate
the *minimum* annual number of human AIV infections as was done in [13], we use numerical
methods to estimate the *mean* annual number of human AIV infections. Following [13], we
develop a stochastic model that describes the epidemiological and evolutionary processes that
give rise to an influenza pandemic of zoonotic origin. The quantities that we use to predict the

annual probability of a pandemic are the number of humans infected by zoonotic spillovers, the

transmissibility of AIV in humans, and the probability of, and epidemiological characteristics

that arise from, evolutionary change.

We use a multitype branching process to model human infections with a genotype, i, of an AIV.

Given σ different AIV genotypes, each that are circulating in non-human animal populations

with frequencies, $\rho_1, \rho_2, \ldots, \rho_\sigma$, then the probability mass function for the number of human

infections with AIV is,

$$
\begin{aligned}
P(K_1 = k_1, K_2 = k_2, \ldots, K_\sigma = k_\sigma) &= P\left(N_h = \sum_{i=1}^{\sigma} k_i \frac{1}{1 - R_{0,i}} \right) \\
&= \sum_{n_z} P(N_z = n_z) \times \frac{n_z!}{k_1!\, k_2! \ldots k_\sigma!} \rho_1^{k_1} \rho_2^{k_2} \ldots \rho_\sigma^{k_\sigma}.
\end{aligned}
\tag{1}
$$

The AIV may have evolved to infect other animals besides birds, and we let n_z be the annual

number of zoonotic spillovers (i.e., AIV infections that spread from animals to humans), where

N_z is a random variable describing this quantity. We define $R_{0,i}$ as the basic reproduction number

of an AIV of genotype i introduced to humans prior to any adaptation. This is the number of

secondary human infections generated by a human infected with an AIV in a wholly susceptible

human population before any evolutionary change occurs during any of the subsequent human

infections. This basic reproduction number, $R_{0,i}$, is required to be less than 1 because it is

assumed that the AIV genotype that spills over to humans is not yet adapted for human-to-human

spread [13,12].

The term $\frac{n_z!}{k_1!\, k_2! \ldots k_\sigma!}$ is the possible combinations of numbers of genotypes that make up all the

n_z zoonotic spillovers, which is multiplied by the probability of these combinations occurring,

$\rho_1^{k_1} \rho_2^{k_2} \ldots \rho_\sigma^{k_\sigma}$, and together these two terms describe the probability mass function of a

multinomial distribution, conditioned on a given number of zoonotic spillovers, n_z. The

multiplication by the probability of n_z zoonotic spillovers, $P(N_z = n_z)$, and the sum over n_z

reflects the law of total probability. The righthand side of equation (1) is the probability that the

number of spillovers for each of the genotypes is $K_1 = k_1$, $K_2 = k_2, \ldots, K_\sigma = k_\sigma$, and this is equated

to the probability mass function for the number of human AIV infections, $P(N_h = n_h)$, that occur

for this number of spillovers of each genotype. Specifically, the genotype i is expected to

generate $1/(1-R_{0,i})$ human infections [22], there are k_i instances of zoonotic spillover due to

genotype i, and the total number of human infections is the sum across all genotypes.

There are different subtypes and clades of AIV and these aspects of influenza virology are

represented in our modelling as we consider AIV genotypes, i. Genotypes that have

characteristics, such as high transmissibility in humans, may be more likely to be of a particular

subtype or clade, but our modelling represents only the diversity in the epidemiological

characteristics without associating such characteristics to a particular subtype.

We assume the number of zoonotic spillovers can be modelled by a probability mass
function $P(N_z = n_z)$ with a mean equal to $\bar{n}_z$. Calculating the expected value gives the mean
number of human infections with AIV that occur annually, $\bar{n}_h$, as,

$$\bar{n}_h = \sum_{n_z} P(N_z = n_z) \sum_{k_1,k_2,\dots,k_\sigma} \left(\frac{n_z!}{k_1!\,k_2!\dots k_\sigma!} \rho_1{}^{k_1}\rho_2{}^{k_2}\dots\rho_\sigma{}^{k_\sigma} \times \sum_{i=1}^{\sigma} k_i \frac{1}{1-R_{0,i}} \right), \quad (2)$$

$$= \sum P(N_z = n_z) n_z \bar{m}, \quad (3)$$
$$= \bar{n}_z \bar{m}. \quad (4)$$

As such, the mean annual number of human infections includes both the zoonotic spillovers and
any subsequent human-to-human transmission of AIV. Equation (4) relates the quantity that we
aim to estimate, $\bar{n}_h$, to the mean number of zoonotic spillovers of AIV, $\bar{n}_z$, which we will show
can be estimated from the historical rate of pandemics. The simplification that occurs in equation
(3) is due to the expected value of the function $f(k_i) = k_i \frac{1}{1-R_{0,i}}$ for a multinomial distribution,
which is $n_z \rho_i \frac{1}{1-R_{0,i}}$. We define $\bar{m} = \sum \rho_i \frac{1}{1-R_{0,i}}$ as the mean number of human secondary
infections in a wholly susceptible population where the mean is calculated across all genotypes,
i. The simplification that occurs in equation (4) is due to substituting $\bar{n}_z$ for the expected value of
$P(N_z = n_z)$.

The probability of a pandemic occurring in any year can be modelled as a random
variable Λ with a probability density that is,

$$P\left(\Lambda = 1 - \prod(1-\pi_i)^{k_i}\right) = \sum_{n_z} \frac{e^{-\bar{n}_z}\bar{n}_z{}^{n_z}}{n_z!} \times \frac{n_z!}{k_1!\,k_2!\dots k_\sigma!} \rho_1{}^{k_1}\rho_2{}^{k_2}\dots\rho_\sigma{}^{k_\sigma}, \quad (5)$$

where π_i is the probability that an infection with the genotype i causes a pandemic and Λ is
equated to the event that at least one of the AIV spillovers results in a pandemic. Data describing
the interpandemic periods for seven pandemics that occurred over the last 245 years is used to
estimate the annual probability of a pandemic. The annual probability of a pandemic (which will
be estimated from data as described in (b)) is equated to the expected value of equation (5),
which is

$$\bar{\Lambda} = 1 - \sum_{n_z} P(N_z = n_z)(1-\bar{\pi})^{n_z}. \quad (6)$$

151 The mean probability that a human infection with the AIV genotype i results in a pandemic, $\bar{\pi}$,
152 depends on the probability of a pandemic-capable mutation arising from a single human AIV
153 infection, a_i, and the probability that the pandemic-capable mutation is not lost by random
154 chance. This is

$$\bar{\pi} = \sum_{i=1}^{\sigma} \frac{R_{0,i} - 1 - a_i + \sqrt{(R_{0,i} + 1 + a_i)^2 - 4R_{0,i}(1 + a_i(1 - P_i))}}{2R_{0,i}} \rho_i, \qquad (7)$$

which is equation 2.1a in [13]. The parameter P_i can be understood in terms of the expected
number of secondary infections that the pandemic-capable strain produces in a wholly
susceptible population, R_i^*, where $P_i = 1 - 1/R_i^*$ [12] and $R_i^* > 1$ to satisfy the definition of
pandemic-capable.

Our derivation in this section is similar to [13] except that we focus on the mean, rather than
the minimum, number of human AIV infections (where the latter was the focus of [13]). As such,
we have not used any of the approximations that assume the number of zoonotic spillovers, $\bar{n}_z \bar{\pi}$,
and the genotypic variance are small.

(b) Generating genotypes and estimating the mean number of zoonotic spillovers from data

We used Latin hypercube sampling (LHS) [23] to generate genotypes indexed $i = 1$ to $\sigma = 1{,}000$
by sampling from the distributions described in Table 1 (see section A.1 in S1 Appendix for
parameter distributions). All influenza A subtypes have the potential to cause the emergence of
pandemic strains through reassortment [24] and/or mutation, so we do not specify any particular
HA subtype for the sampled genotypes.

Table 1. Distributions used for LHS to generate genotypes.

Distribution	Meaning	Parameterization	Units and constraints	Reference
R_0	Reproduction number in human population of an AIV prior to evolutionary change	Exponential with a mean of 0.05	Unitless, must be between 0 and 1	Assumed

R^*	Reproduction number in human population of a virus that is a reassortment of a human influenza virus and AIV mutation that is pandemic-capable	Triangular from 1 to 1.1 with a maximum of 2	Unitless, must be greater than 1	Assumed
A	Overall probability that a strain with pandemic potential emerges within any single AIV infection in humans	Uniform between 0.000012 and 0.000024	Unitless, must between 0 and 1	[13]

We fit a gamma distribution to data describing the interpandemic periods of the seven influenza
pandemics of zoonotic origin that occurred during the past 245 years (Fig 1), with a mean, δ, and
scale parameter, θ. The mean annual probability of a pandemic, to be equated with $\bar{\Lambda}$ in equation
(7), is $1/\delta$. The gamma distribution was chosen because this distribution describes the inter-event
wait times arising from a Poisson process. The fitting was performed using the maximum
likelihood approach and was implemented using the bbmle package in R [25].

178
Fig 1. Timeline of influenza pandemics that occurred over the last two centuries with
influenza subtypes (if known) and interpandemic period lengths [26-28]

It has been argued that pandemics are becoming more frequent [29]. As such, we also
hypothesize that the mean of the interpandemic period is affected by the date of past pandemics,
i.e., whereby more recent pandemics may have occurred more frequently. To do this, we let $\delta =$
$\delta_0 + \delta_1 x_d$ where δ_0 and δ_1 are parameters for the intercept and slope of the relationship between
the mean interpandemic period and x_d is the number of years since 1781 (the date of the first
pandemic we consider). We calculate the likelihood ratio for the model with an effect of recency
compared to a model without an effect of recency.

We sampled from our fitted gamma distribution to generate estimates of $\bar{\Lambda}_i$. The sampling
approach incorporates uncertainty in the interpandemic period, some of which is because there
are only a few influenza pandemics reported that occurred during the last centuries. Our
estimation approach does not explicitly consider influenza subtypes because relatively few
pandemics have occurred in the past, such that it is not possible to estimate the annual
probability of a pandemic due to a particular subtype.

(c) Calculating the distribution of the mean annual number of
human AIV infections

We calculated the distribution of the mean annual number of human AIV infections by
completing $\sigma = 1,000$ samples of $R_{0,i}$, P_i (calculated as $= 1 - 1/R_i^*$), a_i, and $\bar{\Lambda}_i$. This sampling
occurred using the lhs package in R. For all the sampled values of $R_{0,i}$, P_i, and a_i, we
calculate $\bar{\pi}$ using equation (7), where the frequency of each genotype is $\rho_i = 1/\sigma$ for all i. We
then calculate $\bar{n}_{z,i}$ by equating the sampled value of $\bar{\Lambda}_i$ with $\bar{\Lambda}$ in equation (6) and solving for
$\bar{n}_z$, which is the only unknown value (and for this specific realization of the sampling is
referred to as $\bar{n}_{z,i}$). The value of $\bar{n}_{z,i}$ is then substituted for $\bar{n}_z$ in equation (4) to estimate one
of the values of $\bar{n}_{h,i}$, where all these values together comprise our estimated distribution for
the mean annual number of human infections with AIV.

(d) Calculating the IFR and the impact of preventing zoonotic spillovers

We calculate the IFR by estimating the annual number of human mortalities due to AIV as 473 reported human mortalities over the last 23 years [15], which is on average 20.6 deaths per year. The IFR is calculated as the annual number of mortalities, divided by the mean annual number of human infections with AIV as estimated in (c), and is expressed as a percentage. We assume that all human fatalities with AIV are reported.

We also investigate the impact of control measures that reduce the mean number of zoonotic AIV spillovers to humans by a fraction, χ. We modify equation (6) to determine how these control measures impact the annual probability of a pandemic as,

$$\Lambda_\chi = 1 - \sum_{n_z} \frac{e^{-\bar{n}_z(1-\chi)}\bar{n}_z(1-\chi)^{n_z}}{n_z!}(1-\bar{\pi})^{n_z}. \tag{8}$$

(e) Comparison to previously estimated minimum annual spillovers

We complete an analysis to compare our results with the minimum annual number of zoonotic spillovers implied by the historical interpandemic period as estimated in [13]. For our comparison, we graph the range of the minimum estimates of the annual zoonotic spillovers using equation (2.1b) from [13], which is,

$$\bar{\Lambda} = \frac{\bar{n}_z}{1 - R_0}aP, \tag{9}$$

in our notation. As is assumed in figure 2 of [13], we consider the minimum and maximum values of a as 0.000012 and 0.000024, the minimum and maximum values of $\bar{\Lambda}$ as 0.007 and 0.076, and we fix $P = 1$. Using this approach, we produce a range for the minimum annual number of zoonotic spillovers as was done in [13].

To estimate an analogous minimum number of zoonotic spillovers using our methodology, we set $P = 1$ for all i, set R_0 to each of 0, 0.2, 0.4, 0.6 and 0.8, and sample from the distributions for the other parameters as described in (b) and (c). Using this approach, we produce a distribution for the minimum annual number of zoonotic spillovers, which we compare to the range that was calculated in [13].

3. Results

We fitted the gamma distribution to the interpandemic periods of past pandemics (see Fig A2 in S1 Appendix) and estimated the mean interpandemic period as $\delta = 38$ years (95% confidence interval: [25, 62]) with $\theta = 8.9$ (95% confidence interval: [2.8, 28.4]). We also fitted a gamma

distribution with a mean that depends on the start date of the past pandemics and estimated $\delta_0 =$
53.5 years (95% confidence interval: [28.3, 102.6]), $\delta_1 = -0.14$ years per year (75% confidence
interval: [-0.27, -0.03]; standard error: 0.10), and $\theta = 9.2$ (95% confidence interval: [2.7, 31.5]).
The likelihood ratio for the model with an effect of recency on the interpandemic period
compared to the model without an effect of recency is 1.99 which means that the start date of the
interpandemic period did not have a clear effect on the mean interpandemic period [30] (see
section A.2 in S1 Appendix for additional details). While the effect of recency on the
interpandemic period is not clear, other studies argue that pandemics are becoming more frequent
[29], so we consider results that incorporate this effect in our subsequent analyses.

Fig 2. (A) Estimated mean annual number of human infections with AIV. The mean interpandemic period of 38 years corresponds to if there is no effect of recency on the interpandemic period (red line). If we assume an effect of recency on the interpandemic period, then the expected interpandemic period in 1781 is 53.5 years (blue line) and 18.5 years in 2026 (orange line). As the distribution of the mean annual number of human infections with AIV is highly right-skewed these estimates are shown on a logarithmic (base 10) scale. (B) Corresponding IFRs.

Fig 3. Estimated IFRs per (10,000 human infections) for AIV with different mean interpandemic periods, compared with SARS-CoV-2 and seasonal influenza.

We sampled from our fitted gamma distribution and created genotypes as described in (c) and evaluated equation (5) to estimate a mean of 6,441 annual human infections with AIV when there is no effect of recency on the interpandemic period (95% confidence interval: [2,736, 21,407]; Fig 2A; red line). This corresponds to an IFR of 20.6/6,441 = 0.32% (95% confidence interval: [0.096%, 0.75%]) which is 32 deaths per 10,000 infections (Fig 2B). For reference, the IFR of SARS-CoV-2 variants in 2020-2023 was estimated as 16 deaths per 10,000 infections [31] and 2.9-6.5 deaths per 10,000 infections for seasonal influenza [32] (Fig 3). These estimates are implied by our calculation of the number of human AIV infections based on the assumed evolutionary and epidemiological process, and the interpandemic periods of the past seven influenza pandemics. The distribution of annual human AIV infections is highly right-skewed, which means that a very large number of human infections with AIV ($\bar{n}_h > 20,000$) is possible, although with low probability (< 0.025), and that the median ($\bar{n}_h = 6,441$) is much lower than the mid-point of the interval ranging from the 2.5th to 97.5th percentile.

We also calculate how our estimated number of human AIV infections would be different if pandemics are becoming more frequent. The first pandemic that we consider occurred in 1781 (Fig 1) and from our statistical analysis, we estimate the mean time to the next pandemic in 1830 is 53.5 years. For an interpandemic period of 53.5 years, we calculate an annual mean number of 4,462 human AIV infections (95% confidence interval: [2,129, 11,825]; Fig 2A, blue line). This corresponds to an IFR of 46 deaths (95% confidence interval: [17, 96]) per 10,000 infections

(Fig 2B). For the year 2026, we estimate the mean interpandemic period as 18.5 years. For an
interpandemic period of 18.5 years, we estimated an annual mean number of 13,136 human AIV
infections (95% confidence interval: [6,214, 36,230]; Fig 2A, orange line). This corresponds to
an IFR of 16 deaths (95% confidence interval: [5.6, 33]) per 10,000 infections (Fig 2B). Details
describing how we calculated the interpandemic period for 1781 and 2026 are provided in
section A.2 of S1 Appendix.

279
Fig 4. The mean (solid line) number of years that the next pandemic is delayed when a
percentage of animal-human AIV spillovers are prevented, with the dark shading
representing the interquartile range and the light shading representing the 95% prediction
interval. Negative values correspond to probabilities, that are often small, that the next
pandemic occurs sooner.

We used our parameter estimates and sampling approach to understand the impact of preventing
zoonotic spillovers on the annual risk of a pandemic as described by equation (8). We estimate
that preventing 5%, 20% and 50% of animal-human AIV spillovers would delay pandemic
emergence by an average of 2, 9.4 and 37.5 years respectively (Fig 4). As the annual probability
of a pandemic occurring is subject to a high level of uncertainty (as modelled by equation 8),
there is some chance, often which is small, that a pandemic can occur sooner than the mean time
to the next pandemic when there is no prevention of zoonotic spillovers. Our estimates of the
effect of preventing zoonotic spillovers on the number of years the next pandemic would be
delayed are subject to a high level of uncertainty (Fig 4).

Fig 5. (A) Estimated distribution of the minimum annual number of zoonotic spillovers of AIV (purple shaded curve). (B) Estimated distribution of the mean annual number of zoonotic spillovers (purple-yellow shaded curves). Grey shaded areas reproduce the results from figure 2 in [13] and span the 95% support interval of the probability of a pandemic occurring in any given year. Light grey shading is an attack rate of 20% and dark grey shading is an attack rate of 10%.

We based our methodology in (a) on [13] but deviated in our approach as we aimed to find the distribution of the mean annual number of human AIV infections rather than the minimum number. We find that our estimates of the minimum annual number of zoonotic AIV spillovers, $\bar{n}_z$ are consistent with [13] (Fig 5A). Our estimates of the mean annual number of zoonotic AIV spillovers, that sample from the distribution for P, are higher (Fig 5B) than both the minimum estimates of [13] (grey shading) and our own minimum estimates (Fig 5A).

4. Discussion

We developed a stochastic model based on epidemiological and evolutionary processes that give rise to pandemics to estimate the number of human infections with AIV that occur each year for the years when a pandemic is not occurring. We estimate that, on average, there are 6,441 annual human infections with AIV worldwide, which is much higher than the 986 human cases reported to date and suggests that many infections are undetected and could be because some humans infected with AIV are asymptomatic or symptomatic but not tested. Based on our estimate of annual AIV infections and the assumption that all AIV deaths in humans are reported, the IFR of 32 deaths per 10,000 infections is much lower than the reported case fatality rate of 48% [15]. The IFR better informs risk of HPAI virus infection to humans that handle infected wildlife as it

includes asymptomatic and undiagnosed individuals [17] and is not biased by the intensity of surveillance activities. The US Centers for Disease Control and Prevention conducted two studies that support that HPAI virus infections are often asymptomatic or symptomatic but not tested [33;34]. One study found that 7% of dairy farm workers tested had antibodies to H5, despite not knowing they had been infected and the other found antibodies in 2% of serum samples from bovine veterinarians [16].

Our estimate of an IFR of 32 deaths per 10,000 human infections with AIV, which is 0.32%, is very high but also with a high degree of uncertainty (95% confidence interval [9.6, 75]). For our model that assumes pandemics are becoming more recent, for 2026, we estimate the IFR as lower: 16 deaths (95% confidence interval: [5.6, 33]) per 10,000 human infections with AIV. The IFR of SARS-CoV-2 variants in 2020-2023 was estimated as 16 deaths per 10,000 infections [31] and 2.9-6.5 deaths per 10,000 infections for seasonal influenza [32]. Therefore, even with the uncertainty in our estimates, both due to the few observations of pandemics that were considered in estimating the IFR and due to uncertainty in whether pandemics are become more recent, our estimate of the IFR for human infections with AIV is similar to, and possibly higher than, the IFR of SARS-CoV-2 variants during the recent pandemic and higher than that of seasonal human influenza.

Given our estimate of a relatively high IFR for human AIV infections, for hunters, trappers, poultry workers, farmers, wildlife officials, veterinarians and other groups that handle wildlife there is a need to be cautious as there is a relatively high chance that human HPAI virus infections can result in severe infections. The primary virulence mechanism of all H5 viruses involves hemagglutinin (HA), which relies on host proteases for cleavage into two subunits required for cell invasion. In HPAI viruses, a polybasic cleavage site is formed by acquiring multiple basic amino acids. This allows cleavage by furin-like proteases which are distributed more broadly in tissues, enabling systemic infection in birds and mammals, which can result in high pathogenicity [16]. Our estimate of a high IFR for human infections with AIV may have some basis in terms of viral virulence mechanisms of HPAI virus.

Efforts to prevent human infections with non-pandemic capable genotypes of HPAI virus are necessary given the high individual risk of severe outcomes (as measured by the IFR), but also to lower the risk of a pandemic emerging in any given year. We estimate that preventing 20% of animal-to-human AIV spillovers annually would delay pandemic emergence by an average of 9.4 years and preventing 50% of spillovers would delay pandemic emergence by 37.5 years. Measures that prevent the spillover of HPAI virus to humans include not touching, feeding or handling potentially infected birds or other animals, when contact cannot be avoided wearing gloves and a well-fitted respirator or medical mask, reporting infected animals to the appropriate animal health authority [7], the humane destruction of infected and exposed animals, and strict quarantine and animal movement controls to prevent disease spread [10].

We found that the pandemic start date had no clear effect on the mean interpandemic
period. The reason that there is not stronger evidence supporting pandemics occurring more
frequently now than in the past, is that there are few observations of pandemics (rather than
abundant data that support no effect), and because arguments have been presented for
mechanisms that would mean pandemics occur more frequently now. These mechanisms include
agricultural expansion, deforestation, urbanization and wildlife trade and consumption. These
activities bring wildlife, livestock, and humans into close contact which can lead to zoonotic
spillovers, epidemics, and pandemics [29]. Increased global connectivity through international
travel, population growth, and climate change further increases the risk of infectious disease
outbreaks [35].

A limitation of our work is that we have inferred the number of human AIV infections
from assumed evolutionary mechanisms, parameter value distributions, and the historical rate of
pandemics, and our analysis includes no verification of these estimates based on diagnostic
testing or serological surveys, such that the validity of our estimates depends on our model
assumptions and parameter distributions. Our modelling assumes that the probability of a
pandemic-capable evolutionary change occurring is constant over time, but this is likely not the
case. Adaption of HPAI virus strains to spread between humans might occur due to reassortment
that occurs when a human is coinfected with HPAI and human influenza viruses, but this risk of
coinfection is variable. The severity of a future HPAI virus pandemic is uncertain as recent
human infections with H5N1 clade 2.3.4.4b viruses have had much lower-case fatality ratios than
in the past with 2 deaths in 71 cases in the US compared with previous outbreaks in Asia where
the case fatality ratio was about 50%. However, it is unclear whether the recent H5N1 virus
infections in humans cause less severe disease or mild cases are merely under-detected in Asia
[16,6,8].

Our approach to estimate the annual number of human AIV infections does not consider
the seasonal and wildlife epidemiologic dynamics of zoonotic spillovers or the seasonality of
human influenza and the probability of a pandemic-capable mutation occurring. Instead, we
assume only seasonal averages for these values, which could result in biased estimation due
Jensen's inequality, which states that using average values in calculations often results in
inaccuracies. We also do not consider the spatial components of AIV spread, such that our
estimates are for the number of human AIV infections that occur worldwide, and our modelling
approach is not sufficient to inform where these infections might be occurring in any given year,
or how these infections could change between years. Future directions of this work include
adding temporal and spatial structure to the model to better inform when, and where, our inferred
number of human AIV infections are occurring.

Given the recent outbreaks of HPAI virus in mammals, it is necessary to communicate the
risk to humans and to explain the rationale for preventative measures. One component of risk to
hunters, trappers, poultry workers, farmers, wildlife officials, veterinarians and other groups that
handle wildlife is the chance that they are handling an infected animal, and initiatives such as

AviFluMap and similar projects in the United States and Europe [36], aim to estimate this component of risk. Another component of risk is the probability of a severe outcome given a human AIV infection, and estimating this quantity was the focus of our study. The strength of our work has been to estimate undetected AIV infections by combining sources given the few data that are available to estimate this quantity. These data were past records of pandemics, and this approach is reasonable given that there are few serological surveillance activities to detect asymptomatic and other untested human AIV infections. We estimate that the IFR of human AIV infections is high relative to human influenza, and possibly SARS-CoV-2, such that individuals that take measures to prevent AIV infections would avoid the high risk of a severe outcome. We also show that the value of preventing human AIV infections extends beyond the individual, as preventing human AIV infections delays the emergence of a global pandemic. Our results quantify the value of preventing human AIV infections to both the individual and to society.

Acknowledgements

We acknowledge comments on the manuscript from Andrew Lang, Joseph Baafi, Francis Anokye, Abdou Fofana and Giuseppe Pasqualino.

References

1. Belshe RB. The origins of pandemic influenza—lessons from the 1918 virus. N Engl J Med. 2005;353: 2209–2211. doi:10.1056/NEJMp058281

2. Steel J, Lowen AC. Influenza A virus reassortment. Curr Top Microbiol Immunol. 2014;385: 377–401. doi:10.1007/82_2014_395

3. Rahman I, Erdelyan CNG, Signore AV, Ayilara I, Wight J, Jones MEB, et al. Recurring incursions and dissemination of novel Eurasian-origin H5Nx avian influenza viruses in Atlantic Canada. Virus Evol. 2024;10: veae111. doi:10.1093/ve/veae111

4. Giacinti JA, Signore AV, Jones MEB, Bourque L, Lair S, Jardine C, et al. Avian influenza viruses in wild birds in Canada following incursions of highly pathogenic H5N1 virus from Eurasia in 2021–2022. mBio. 2024;15: e03203-23. doi:10.1128/mbio.03203-23

5. Avery Gomm S, Barychka T, English M, Ronconi R, Wilhelm SI, Rail JF, et al. Wild bird mass mortalities in eastern Canada associated with the highly pathogenic avian influenza A(H5N1) virus, 2022. Ecosphere. 2024;15: e4980. doi:10.1002/ecs2.4980

6. Centers for Disease Control and Prevention. H5 bird flu: Current situation [Internet]. 2026 Mar 6 [cited 2026 Mar 24]. Available from: https://www.cdc.gov/bird-flu/situation-summary/index.html

7. Public Health Agency of Canada. Avian influenza A(H5N1): Spread, prevention and risks [Internet]. 2025 Jul 10 [cited 2025 Oct 20]. Available from: https://www.canada.ca/en/public-health/services/diseases/avian-influenza-h5n1/prevention-risks.html

8. Peacock TP, Moncla L, Dudas G, VanInsberghe D, Sukhova K, Lloyd-Smith JO, et al. The global H5N1 influenza panzootic in mammals. Nature. 2025;637: 304–313. doi:10.1038/s41586-024-08054-z

9. World Health Organization. Virology of human influenza [Internet]. 2010 May 13 [cited 2025 Dec 20]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/virology-of-human-influenza

10. Canadian Food Inspection Agency [Internet]. Ottawa (ON): Canadian Food Inspection Agency; 2025 Aug 12 [cited 2026 Jan 15]. Available from: https://inspection.canada.ca/en/animal-health/terrestrial-animals/diseases/reportable/avian-influenza/facts-about-avian-influenza

11. Plowright RK, Ahmed AN, Coulson T, Crowther TW, Ejotre I, Faust CL, et al. Ecological countermeasures to prevent pathogen spillover and subsequent pandemics. Nat Commun. 2024;15: 2577. doi:10.1038/s41467-024-46151-9

12. André JB, Day T. The effect of disease life history on the evolutionary emergence of novel pathogens. Proc R Soc B. 2005;272: 1949–1956. doi:10.1098/rspb.2005.3170

13. Day T, André JB, Park A. The evolutionary emergence of pandemic influenza. Proc R Soc B. 2006;273: 2945–2953. doi:10.1098/rspb.2006.3638

14. Ramey AM, Hill NJ, DeLiberto TJ, Gibbs SEJ, Hopkins MC, Lang AS, et al. Highly pathogenic avian influenza is an emerging disease threat to wild birds in North America. J Wildl Manage. 2022;86: e22171. doi:10.1002/jwmg.22171

15. World Health Organization. Avian influenza A(H5N1) – Cambodia [Internet]. 2025 Jul 5 [cited 2025 Dec 2]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON575

16. Drake JM. Understanding avian influenza mortality: Three theories could explain why the North American H5N1 epidemic has not been more deadly. Science. 2025;389: 1292–1294. doi:10.1126/science.adx7159

17. Böttcher L, Xia M, Chou T. Why case fatality ratios can be misleading: individual- and population-based mortality estimates and factors influencing them. Phys Biol. 2020;17: 065003. doi:10.1088/1478-3975/ab9e59

18. Fatoyinbo H, Tiwari P, Olanipekun PO, Ghosh I. A mathematical model of HPAI transmission between dairy cattle and wild birds with environmental effects. arXiv. 2025. doi:10.48550/arXiv.2508.12201

19. Chang Y, Gonzales JL, Reimert MM, Rattenborg E, de Jong MCM, Conrady B. Assessing the spatial and temporal risk of HPAIV transmission to Danish cattle via wild birds. arXiv. 2025. doi:10.48550/arXiv.2504.12432

20. Cherian P, Menon GI. Modelling a potential zoonotic spillover event of H5N1 influenza. BMC Public Health. 2025;25: 3983. doi:10.1186/s12889-025-25358-5

21. Yang Y, Halloran ME, Sugimoto JD, Longini IM. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis. 2007;13: 1348–1353. doi:10.3201/eid1309.070111

22. Miller JC. A primer on the use of probability generating functions in infectious disease modeling. Infect Dis Model. 2018;3: 192–248. doi:10.1016/j.idm.2018.08.001

23. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int Stat Rev. 1994;62: 229–243. doi:10.2307/1403510

24. Webster RG, Hulse DJ. Microbial adaptation and change: Avian influenza. Rev Sci Tech. 2004;23: 453–465. doi:10.20506/rst.23.2.1493

25. Bolker B, R Development Core Team. bbmle: Tools for general maximum likelihood estimation, version 1.0.26; 2025 [cited 2025 Oct 20]. Software: GitHub [Internet]. Available from: https://github.com/bbolker/bbmle

26. Romaniello MP. The influential influenza: The "Russian catarrh" pandemic of 1781–1782. J Hist Med Allied Sci. 2024:1–16. doi:10.1093/jhmas/jrae025

27. Dowdle WR. Influenza A virus recycling revisited. Bull World Health Organ. 1999;77: 820–828.

28. Hajjar SA, McIntosh K. The first influenza pandemic of the 21st century. Ann Saudi Med. 2010;30: 1–10. doi:10.5144/0256-4947.59365

29. Daszak P, das Neves CG, Amuasi J, Hayman D, Kuiken T, Roche B, et al. Workshop Report on Biodiversity and Pandemics of the Intergovernmental Platform on Biodiversity and Ecosystem Services (IPBES); 2020 [cited 2026 Mar 28]. Database: Zenodo [Internet]. Available from: https://doi.org/10.5281/zenodo.4147317

30. Deeks JJ, Altman DG. Diagnostic tests 4: Likelihood ratios. BMJ. 2004;329: 168–169. doi:10.1136/bmj.329.7458.168

31. Riedmann U, Chalupka A, Richter L, Sprenger M, Rauch W, Krause R, et al. COVID-19 case fatality rate and infection fatality rate from 2020 to 2023: Nationwide analysis in Austria. J Infect Public Health. 2025;18: 102698. doi:10.1016/j.jiph.2025.102698

32. World Health Organization. Influenza (seasonal) [Internet]. 2025 Feb 28 [cited 2025 Dec 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)

33. Mellis AM, Coyle J, Marshall KE, Lucero-Obusan C, Kelleher AD, Lehman CW, et al. Serologic evidence of recent infection with highly pathogenic avian influenza A(H5) virus among dairy workers—Michigan and Colorado, June–August 2024. MMWR Morb Mortal Wkly Rep. 2024;73: 1004–1009. doi:10.15585/mmwr.mm7344a3

34. Leonard J, Harker EJ, Szablewski CM, Margrey SF, Gingrich KF 2nd, Crossley K, et al. Notes from the field: Seroprevalence of highly pathogenic avian influenza A(H5) virus infections among bovine veterinary practitioners—United States, September 2024. MMWR Morb Mortal Wkly Rep. 2025;74: 50–52. doi:10.15585/mmwr.mm7404a2

35. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022;20:193–205. doi:10.1038/s41579-021-00639-z

36. Ross TA, Ryding S, Lisovski S, Driessen J, Mowat E, Todd S, et al. AviFluMap: An interactive tool to assess H5N1 avian influenza incursion risk in Australia via migratory birds. Ecol Inform. 2026;93: 103603. doi:10.1016/j.ecoinf.2026.103603

Supporting information

S1 Appendix

A.1 Parameter distributions

Fig A1. shows the sampled values of the parameters that were used to estimate the mean annual number of human AIV infections, where σ genotypes are created by sampling from plausible trait values.

A

B

C

Fig A1. Sampled values of three parameters, where these samples are the basis for the estimated annual number of human AIV infections shown in Fig 2.

A.2 Distribution of interpandemic periods

Fig A2. shows the fitted gamma distribution to the interpandemic periods of the seven influenza pandemics of zoonotic origin that occurred during the past 245 years (Fig 1) with no effect of recency on the mean interpandemic period.

Fig A2. A gamma distribution fitted to observations of the interpandemic periods (black dots) of the seven influenza pandemics that occurred during the last 245 years with no effect of recency on the mean interpandemic period.

For our analysis of the effect of pandemic start date on the mean interpandemic period, we estimate that $\delta_1 = -0.14$ (75% confidence interval: [-0.27, -0.029]). The parameter estimate for δ_1 means that there are 14 years less between pandemics that occur a century later (Fig A3). Based on these estimates, the mean interpandemic period for our earliest record in 1781 is 53.5 years and for the present, which we take to be 2026, the mean interpandemic period is 53.5 - 245 × 0.14 which is about 18.5 years until the next pandemic. To investigate the impact of pandemics occurring more recently in recent times, we consider these interpandemic periods for 1781 and 2026 in Fig 2A.

536
537 **Fig A3. Effect of pandemic start date on the mean interpandemic period.**

539